A5103158358- Cancer Genomics and Diagnostics
- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Cancer Immunotherapy and Biomarkers
- Transplantation: Methods and Outcomes
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Cardiomyopathy and Myosin Studies
- Renal Diseases and Glomerulopathies
- Gene expression and cancer classification
- Genetic factors in colorectal cancer
- Electrolyte and hormonal disorders
- Lung Cancer Treatments and Mutations
- Neuroendocrine regulation and behavior
- Molecular Biology Techniques and Applications
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Organ Donation and Transplantation
- Viral Infections and Immunology Research
- Bladder and Urothelial Cancer Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroscience of respiration and sleep
- Urinary and Genital Oncology Studies
- RNA Research and Splicing
- Cardiac electrophysiology and arrhythmias
University of Basel
2019-2025
University Hospital of Basel
2023-2025
Medizinische Hochschule Hannover
2016-2022
Universitätsmedizin Göttingen
2015-2022
Japan Patent Office
2021
Sonnenhalde (Switzerland)
2019
University of Freiburg
2014-2018
Helix Biomedix (United States)
2010
Vanderbilt University
2010
BACKGROUND Cell-free DNA (cfDNA) from grafts in the circulation of transplant recipients is a potential biomarker rejection. Its usefulness was investigated after heart transplantation during maintenance phase by use microarrays and massive parallel sequencing donor recipient DNA. Disadvantages these methods are high costs, long turnaround times, need for Therefore, we sought to develop rapid cost-effective method using digital droplet PCR (ddPCR). METHODS Plasma samples were collected...
Background Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, a promising noninvasive organ integrity biomarker. In liver transplantation (LTx), neither conventional function tests (LTFs) nor immunosuppressive drug monitoring are very effective for rejection monitoring. We therefore hypothesized that quantitative measurement of donor-derived (cfDNA) would have independent value assessment graft integrity, including damage from acute...
Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive biomarker for comprehensive monitoring of allograft injury and rejection in kidney transplantation (KTx). dd-cfDNA quantification copies/mL plasma (dd-cfDNA[cp/mL]) was compared to fraction (dd-cfDNA[%]) at prespecified visits 189 patients over 1 year post KTx. In (N = 15, n 22 samples) with biopsy-proven (BPR), median dd-cfDNA(cp/mL) 3.3-fold dd-cfDNA(%) 2.0-fold higher (82 cp/mL; 0.57%, respectively) than medians Stable Phase 83, 408)...
Transplant recipients exhibit an impaired protective immunity after SARS-CoV-2 vaccination, potentially caused by mycophenolate (MPA) immunosuppression. Recent data from patients with autoimmune disorders suggest that temporary MPA hold might greatly improve booster vaccination outcomes. We applied a fourth dose of vaccine to 29 kidney transplant during (5 weeks) MPA/azathioprine hold, who had not mounted humoral immune response previous vaccinations. Seroconversion until day 32 was observed...
Purpose: Chromosomal instability is a fundamental property of cancer, which can be quantified by next-generation sequencing (NGS) from plasma/serum-derived cell-free DNA (cfDNA). We hypothesized that cfDNA could used as real-time surrogate for imaging analysis disease status function response to immunotherapy and more reliable tool than tumor biomarkers.Experimental Design: Plasma sequences 56 patients with diverse advanced cancers were prospectively collected analyzed in single-blind study...
Background Muscle-invasive urothelial cancer (UC) has a high risk of recurrence after definitive treatment. Nivolumab adjuvant to radical surgery improves disease-free survival in patients with UC recurrence; however, its role chemoradiation therapy (CRT) is unknown. Methods The NEXT trial single-arm, phase-2 study evaluating the efficacy and tolerability nivolumab CRT localized or locoregional UC. primary endpoint failure-free (FFS) at 2 years. Secondary endpoints include patterns...
Abstract Background: Circulating nucleic acids (CNAs) have been shown to diagnostic utility in human diseases. The aim of this study was sequence and organize CNAs document typical profiles circulating DNA apparently healthy individuals. Methods: Serum from 51 humans extracted, amplified, sequenced via pyrosequencing (454 Life Sciences/Roche Diagnostics), categorized by (a) origin (human vs xenogeneic), (b) functionality (repeats, genes, coding or noncoding), (c) chromosomal localization....
IntroductionThe WHO classification of pulmonary neuroendocrine tumors (PNETs) is also used to classify thymic NETs (TNETs) into typical and atypical carcinoid (TC AC), large cell carcinoma (LCNEC), small (SCC), but little known about the usability alternative systems.MethodsOne hundred seven TNET (22 TC, 51 AC, 28 LCNEC, 6 SCC) from 103 patients were classified according WHO, European Neuroendocrine Tumor Society, a grading-related PNET classification. Low coverage whole-genome sequencing...
Circulating nucleic acids (CNA) isolated from serum or plasma are increasingly recognized as biomarkers for cancers. Recently developed next generation sequencing provides high numbers of DNA sequences to detect the trace amounts unique associated with breast carcinoma. Serum CNA 38 women ductal carcinoma was extracted and sequenced on a 454/Roche high-throughput GS-FLX platform compared healthy controls patients other medical conditions. Repetitive elements present in were detected...
Immunosuppressant therapeutic ranges for transplant patients have traditionally been established by indirect clinical means. However, "liquid biopsy" methods measuring graft-derived cell-free DNA (GcfDNA) in blood directly interrogate donor organ integrity. This study was performed to determine whether GcfDNA quantification could be used reexamine minimally effective trough tacrolimus (Tacro) concentrations liver transplantation (LTx) patients.As part of a large prospective demonstrate the...
Abstract BACKGROUND Genomic instability resulting in copy number variation is a hallmark of malignant transformation and may be identified through massive parallel sequencing. Tumor-specific cell free DNA (cfDNA) present serum plasma provides real-time, easily accessible surrogate. METHODS was extracted from 204 patients with prostate cancer (Gleason score 2–10), 207 male controls, benign hyperplasia (n = 10) prostatitis 10). amplified by use random primers, tagged molecular identifiers,...
Hypertrophic Cardiomyopathy (HCM) has been related to many different mutations in more than 20 different, mostly sarcomeric proteins. While development of the HCM-phenotype is thought be triggered by mutations, a common mechanism remains elusive. Studying missense-mutations ventricular beta-myosin heavy chain (β-MyHC, MYH7) we hypothesized that significant contractile heterogeneity exists among individual cardiomyocytes HCM-patients results from cell-to-cell variation relative expression...
Donor-derived cell-free DNA (dd-cfDNA) is reportedly a valuable tool for graft surveillance following kidney transplantation (KTx). Possible changes in dd-cfDNA(%) reference values over time have not been evaluated. For long-term monitoring after KTx, host cfDNA might represent biasing factor determinations.Plasma samples were obtained (n = 929) 12-60 months engraftment cross-sectional cohort of 303 clinically stable KTx recipients. Total cfDNA(copies/mL), dd-cfDNA(%), and...
The analysis of circulating cell free DNA is an important tool for the tumor resistance, heterogeneity, detection minimal residual disease and allograft rejection in kidney or heart transplant patients. proper use this technique important, starts with considering pre-analytic aspects. current paper addresses some technical considerations to ensure harmonized cfDNA techniques.
Cigarette smoking cessation reduces cardiovascular risk via various mechanisms. Thereby, the role of blood pressure remains unclear, with studies reporting both decreased and increase values after cessation, potentially influenced by weight change. We previously showed that glucagon like peptide-1 analogue dulaglutide mitigates gain cessation. This secondary analysis investigates effect on changes in dulaglutide- vs. placebo-treated individuals. hypothesized a beneficial pressure,...
Distinguishing arginine vasopressin (AVP) deficiency from primary polydipsia remains challenging. While hypertonic saline-stimulated copeptin testing offers high diagnostic accuracy, it is complex and limited to specialized centers. Intravenous urea known stimulate AVP secretion, but the effect of oral on levels unknown. 22 healthy adults were included in a randomized, double-blind, placebo-controlled cross-over trial receiving single dose (0.5 g/kg; minimum 30 g, maximum 45 g) placebo....
Background. Circulating graft-derived cell-free DNA (dd-cfDNA) is a new marker of cardiac allograft damage that used for noninvasive rejection diagnostics. We performed dd-cfDNA (%) in heart transplant recipients during the first posttransplant year. Methods. In 87 patients, serial determination at predefined time-points was 770 single samples. fraction measured using an established universal droplet digital polymerase chain reaction method, providing same-day turn-around. Rejection...
Background. Donor-derived cell-free DNA (dd-cfDNA) is increasingly recognized as a valuable biomarker for acute transplant injury, with possible indications in the detection of cellular or humoral rejection and guidance immunosuppressive therapy. There an ongoing debate on whether relative absolute quantification dd-cfDNA more reliable injury. Methods. We retrospectively reviewed all 22 kidney recipients who underwent measurements (percentage absolute) between April 2020 2021 at our...